Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells.
D000818:Animals; D000963:Antimetabolites / Q000008:administration & dosage / Q000494:pharmacology; D002455:Cell Division; D003561:Cytarabine / Q000008:administration & dosage / Q000494:pharmacology*; D004273:DNA, Neoplasm / Q000096:biosynthesis*; D007939:Leukemia L1210 / Q000378:metabolism*; D051379:Mice; D013936:Thymidine / Q000378:metabolism; D014316:Tritium
D000963:Antimetabolites; D004273:DNA, Neoplasm; D003561:Cytarabine; D014316:Tritium; D013936:Thymidine